Lupin Wins Fight Over Generic Version of Iroko Pain Drug

Feb. 5, 2018, 9:46 PM

Iroko Pharmaceuticals LLC failed to show a Lupin Pharmaceuticals LLC generic infringed one of its arthritis pain drugs, dealing another blow to the Philadelphia company.

A Maryland district court dismissed an Iroko suit Feb. 1 alleging Lupin’s generic version of Iroko’s Vivlodex osteoarthritis pain tablet infringed U.S. Patent Nos. 9,526,734 and 9,649,318. The patents expire in 2033 and 2035, respectively, according to the Food and Drug Administration’s Orange Book.

Iroko has been struggling in the face of generic competition from Lupin. The FDA approved Lupin’s generic version of Iroko’s Zorvolex (diclofenac), also for osteoarthritis pain, in December 2016. ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.